Literature DB >> 35145127

Early experience of laparoscopic resection and comparison with open surgery for gastric gastrointestinal stromal tumor: a multicenter retrospective study.

Shin-Hoo Park1, Hyuk-Joon Lee2,3,4, Min-Chan Kim5, Jeong-Hwan Yook6, Tae-Sung Sohn7, Woo-Jin Hyung8, Seung-Wan Ryu9, Yukinori Kurokawa10, Young-Woo Kim11, Sang-Uk Han12, Hyung-Ho Kim13, Do-Joong Park1,14, Wook Kim15, Sang-Il Lee16, Haruhiko Cho17,18, Gyu-Seok Cho19, Jin-Jo Kim20, Ki-Han Kim5, Moon-Won Yoo6, Han-Kwang Yang1,14,21.   

Abstract

The advantages of laparoscopic resection over open surgery in the treatment of gastric gastrointestinal stromal tumor (GIST) are not conclusive. This study aimed to evaluate the postoperative and oncologic outcome of laparoscopic resection for gastric GIST, compared to open surgery. We retrospectively reviewed the prospectively collected database of 1019 patients with gastric GIST after surgical resection at 13 Korean and 2 Japanese institutions. The surgical and oncologic outcomes were compared between laparoscopic and open group, through 1:1 propensity score matching (PSM). The laparoscopic group (N = 318) had a lower rate of overall complications (3.5% vs. 7.9%, P = 0.024) and wound complications (0.6% vs. 3.1%, P = 0.037), shorter hospitalization days (6.68 ± 4.99 vs. 8.79 ± 6.50, P < 0.001) than the open group (N = 318). The superiority of the laparoscopic approach was also demonstrated in patients with tumors larger than 5 cm, and at unfavorable locations. The recurrence-free survival was not different between the two groups, regardless of tumor size, locational favorableness, and risk classifications. Cox regression analysis revealed that tumor size larger than 5 cm, higher mitotic count, R1 resection, and tumor rupture during surgery were independent risk factors for recurrence. Laparoscopic surgery provides lower rates of complications and shorter hospitalizations for patients with gastric GIST than open surgery.
© 2022. The Author(s).

Entities:  

Mesh:

Year:  2022        PMID: 35145127      PMCID: PMC8831629          DOI: 10.1038/s41598-022-05044-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Gastrointestinal stromal tumors (GISTs) are the commonest type of mesenchymal tumors of the gastrointestinal tract, with the stomach (50–60%) being the most frequent primary site[1]. Although tyrosine kinase inhibitors (TKIs) have significantly improved disease-free survival, complete R0 surgical resection remains the standard treatment for primary non-metastatic gastric GIST[2-4]. Laparoscopic surgery for gastric GIST has been widely performed to meet the current demand for minimal invasiveness. Numerous studies have reported the potential advantages of laparoscopic resection for gastric GISTs, such as earlier return of bowel function, less blood loss, and shorter hospitalization days[5,6]. However, the perceived advantages of laparoscopic resection compared with open surgery is not conclusive in the treatment of gastric GIST. Previous studies have lacked reliability and credibility for the following reasons. Since gastric GISTs are rare, with an estimated incidence of 1.5/100,000 per year[7,8], no randomized controlled trial (RCT) has clearly demonstrated the beneficial effect of laparoscopic resection of gastric GIST[9,10]. Therefore, the meta-analyses to date are based on the data extracted from non-RCTs; thus, they have less powerful outcomes[11-14]. In addition, retrospective observational studies that reported similar or even better postoperative laparoscopy results suffer from selection bias since laparoscopic surgeries are preferred for smaller sized tumors with favorable locations[6,15]. Several retrospective studies using propensity score matching (PSM) have been conducted to overcome these limitations. However, the small sample sizes have not been sufficient for clear conclusions, and subgroup analyses were not conducted for patients with tumors larger than 5 cm and in unfavorable locations, simultaneously[16,17]. Although, Xiong et al.[18] analyzed 1,027 patients, the largest number ever, only 128 patients were remained for analysis in each group after PSM. Considering the technical advances in laparoscopic surgery over decades, it is meaningful to prove whether laparoscopic surgery was superior to open resection in gastric GISTs treatment even in the early era of laparoscopic surgery. This multi-center retrospective study enrolled 1019 patients diagnosed with gastric GIST after surgery during the period 2000–2007 at 13 Korean and 2 Japanese institutions, aimed to evaluate whether the laparoscopic resections was superior clinical outcomes and comparable in oncologic safety compared to open surgery, even in the early era of laparoscopic surgery. We also evaluated whether the application of laparoscopic surgery could be feasible and safe in tumors larger than 5 cm and in unfavorable locations.

Results

Before PSM, the laparoscopic group had more patients with a higher propensity score, younger age, tumors ≤ 5 cm, and tumors in a favorable location than the open group. The open group had more cases of gastrectomy, combined resection, higher mitotic count, high-risk by NIH classification, and adjuvant chemotherapy than the laparoscopic group. Except for the missing data, there was no difference between the two groups in immunohistochemical parameters including CD117 and CD34. After 1:1 PSM, the 318 patients in the laparoscopic group were matched to the 318 patients in the open group in the same period and the distribution of cumulative cases per year has similar distributional tendency with those observed before matching (Supplementary Fig. 1). And, the propensity scores, clinicopathologic variables were all balanced between the laparoscopic and open groups (Table 1). The distribution of the propensity score was more concentrated, and the absolute SMDs of matching covariates decreased near or below 0.1 (Supplementary Fig. 2).
Table 1

The clinicopathologic characteristics between the laparoscopic group and open group.

VariablesBefore PSMP valueAfter PSMP value
Laparoscopic group(n = 373)Open group(n = 542)Laparoscopic group(n = 318)Open group(n = 318)
Propensity scores
0.5 ± 0.10.3 ± 0.2 < 0.0010.5 ± 0.20.5 ± 0.20.056
Age, years (mean ± SD)
57.1 ± 11.460.0 ± 12.00.01957.4 ± 11.358.4 ± 11.30.245
Sex
Male175 (46.9)272 (50.2)0.346148 (46.5)150 (47.2)0.937
Female198 (53.1)270 (49.8)170 (53.5)168 (52.8)
BMI, kg/m2 (mean ± SD)
24.3 ± 3.124.0 ± 3.10.17924.2 ± 3.024.2 ± 3.10.859
Underlying disease
Hypertension98 (26.4)170 (31.2)0.12184 (26.4)103 (32.4)0.117
Cardiovascular17 (4.6)23 (4.2)0.87013 (4.1)15 (4.7)0.847
Cerebrovascular3 (0.8)3 (0.6)0.6912 (0.6)1 (0.3)0.563
Pulmonary disease19 (5.1)26 (4.8)0.87715 (4.7)19 (6.0)0.598
Hepatic disease22 (5.9)25 (4.6)0.36627 (8.5)36 (11.3)0.288
Diabetes mellitus30 (8.1)64 (11.8)0.07719 (6.0)17 (5.3)0.864
Renal disease2 (0.5)1 (0.2)0.5692 (0.6)1 (0.3)0.563
Radicality of resection
R0 resection368 (98.7)533 (98.3)0.790313 (98.4)313 (98.4)1.000
R1 resection5 (1.3)9 (1.7)5 (1.6)5 (1.6)
Extent of resection
Wedge resection343 (92.0)370 (68.3) < 0.001291 (91.5)288 (90.6)0.950
Partial gastrectomy21 (5.6)88 (16.2)21 (6.6)22 (6.9)
Total gastrectomy2 (0.5)78 (14.4)2 (0.6)3 (0.9)
Enucleation7 (1.9)6 (1.1)4 (1.3)5 (1.6)
Combined resection
Total29 (7.8)83 (15.3) < 0.00127 (8.5)20 (6.3)0.363
Cholecystectomy23 (6.2)19 (3.5)21 (6.6)12 (3.8)
Liver resection2 (0.5)5 (0.9)2 (0.5)1 (0.3)
Colon resection1 (0.3)17 (3.1)1 (0.3)2 (0.5)
Adrenalectomy1 (0.3)7 (1.3)1 (0.3)1 (0.3)
SB resection1 (0.3)3 (0.6)1 (0.3)1 (0.3)
Splenectomy0 (0)40 (7.4)0 (0)1 (0.3)
Pancreatectomy0 (0)20 (3.7)0 (0)1 (0.3)
Others3 (0.8)1 (0.3)3 (0.8)1 (0.3)
Tumor size, mean (mm)
37.3 ± 18.665.2 ± 46.5 < 0.00138.3 ± 19.540.1 ± 17.00.217
Tumor size category (cm)
 > 0, ≤ 262 (16.6)42 (7.7) < 0.00152 (16.4)38 (11.9)0.554
 > 2, ≤ 5247 (66.2)241 (44.5)202 (63.5)206 (64.8)
 > 5, ≤ 749 (13.1)96 (17.7)49 (15.4)58 (18.2)
 > 7, ≤ 1010 (2.7)67 (12.4)10 (3.1)11 (3.5)
 > 10, ≤ 155 (1.3)69 (12.7)5 (1.6)5 (1.6)
 > 15, ≤ 200 (0)17 (3.1)0 (0)0 (0)
 > 20, ≤ 300 (0)9 (1.7)0 (0)0 (0)
 > 300 (0)1 (0.2)0 (0)0 (0)
Longitudinal location
GEJ to Cardia59 (15.8)81 (14.9)0.54053 (16.7)40 (12.6)0.417
Upper third153 (41.0)234 (43.2)129 (40.6)146 (45.9)
Upper to middle1 (0.3)2 (0.4)1 (0.3)0 (0)
Middle third67 (18.0)96 (17.7)57 (17.9)47 (14.8)
Middle to lower0 (0)5 (0.9)1 (0.3)1 (0.3)
Lower third93 (24.9)123 (22.7)77 (24.2)83 (26.1)
Entire length0 (0)1 (0.2)0 (0)1 (0.3)
Circumferential location
Greater110 (29.5)141 (26.0)0.00196 (30.2)89 (28.0)0.231
Lesser80 (21.4)139 (25.6)68 (21.4)78 (24.5)
Anterior93 (24.9)90 (16.6)74 (23.3)58 (18.2)
Posterior90 (24.1)163 (30.1)80 (25.2)91 (28.6)
Entire0 (0)9 (1.7)0 (0)2 (0.6)
Locational preference
Favorable176 (47.2)203 (37.5)0.004145 (45.6)130 (40.9)0.262
Unfavorable197 (52.8)339 (62.5)173 (54.4)188 (59.1)
Mitotic rate (per 50 HPF)
 ≤ 5276 (74.0)352 (64.9) < 0.001242 (76.1)242 (76.1)0.225
 > 5, ≤ 1071 (19.0)96 (17.7)56 (17.6)46 (14.5)
 > 1026 (7.0)94 (17.3)20 (6.3)30 (9.4)
NIH risk stratification
Very low49 (13.1)36 (6.6) < 0.00141 (12.9)32 (10.1)0.232
Low183 (49.1)183 (33.8)157 (49.4)160 (50.3)
Intermediate100 (26.8)128 (23.6)85 (26.7)76 (23.9)
High41 (11.0)195 (36.0)35 (11.0)50 (15.7)
CD 117
Yes306 (97.1)366 (98.4)0.303260 (96.7)202 (99.0)0.125
No9 (2.9)6 (1.6)9 (3.3)2 (1.0)
Unidentified58 cases170 cases49 case114 case
CD 34
Yes281 (98.6)333 (97.9)0.762241 (98.8)186 (98.4)0.752
No4 (1.4)7 (2.1)3 (1.2)3 (1.6)
Unidentified88 case202 case74 case129 case
Adjuvant treatment (Gleevec)
Yes7 (1.9)52 (9.6) < 0.0017 (2.2)7 (2.2)1.000
No366 (98.1)490 (90.4)311 (97.8)311 (97.8)

GEJ gastroesophageal junction, HPF high power field, PSM propensity score matching, SD standard deviation, SB small bowel.

The clinicopathologic characteristics between the laparoscopic group and open group. GEJ gastroesophageal junction, HPF high power field, PSM propensity score matching, SD standard deviation, SB small bowel.

Surgical outcomes and complications before and after PSM

The rates of overall complications were significantly lower in the laparoscopic group than in the open group, either before (4.0% vs. 8.3%, P = 0.010) or after PSM (3.5% vs. 7.9%, P = 0.024). The complication requiring major intervention were lower in the laparoscopic group than in the open group, either before (2.1% vs. 5.5%, P = 0.011) or after PSM (1.9% vs. 5.7%, P = 0.020). The laparoscopic group had lower wound complications than the open group (0.6% vs. 3.1%, P = 0.037) after PSM. Intestinal motility disorder was not found in the laparoscopic group but was found in the open group. The hospitalization days of the laparoscopic group were significantly shorter than those of the open group, either before (6.7 ± 4.9 vs. 10.2 ± 7.7, P < 0.001) or after PSM (6.7 ± 5.0 vs. 8.8 ± 6.5, P < 0.001). The mortality rate within 30 days was not different between the two groups, regardless of PSM (Table 2).
Table 2

Operative outcomes and surgical complications of gastric GIST patients treated by laparoscopic versus open resection.

VariableBefore PSMP valueAfter PSMP value
Laparoscopic group(N = 373)Open group(N = 542)Laparoscopic group(N = 318)Open group(N = 318)
Operation time (minute)
 Overall113.9 ± 58.6125.5 ± 71.30.011114.0 ± 57.0100.8 ± 54.50.003
 Wedge resection or enucleation112.0 ± 58.6103.4 ± 59.70.052111.7 ± 56.997.4 ± 53.70.002
 Gastrectomy143.7 ± 51.1175.4 ± 70.20.014143.1 ± 50.3143.6 ± 46.30.973
Conversion to open surgery14 (3.8)11 (3.5)
Tumor rupture during surgery0 (0)13 (2.4)0.0010 (0)6 (1.9)0.031
Hospital days (mean ± SD)
 Overall6.7 ± 4.910.1 ± 7.7 < 0.0016.7 ± 5.08.8 ± 6.5 < 0.001
 Wedge resection or enucleation6.5 ± 4.89.2 ± 7.8 < 0.0016.4 ± 4.98.7 ± 6.7 < 0.001
 Gastrectomy9.8 ± 5.612.0 ± 7.20.0948.8 ± 2.69.4 ± 2.30.389
Postoperative complications
 Total number of cases with complication15 (4.0)45 (8.3)0.01011 (3.5)25 (7.9)0.024
  Wound4 (1.1)13 (2.4)0.2122 (0.6)10 (3.1)0.037
  Fluid collection1 (0.3)6 (1.1)0.2511 (0.3)1 (0.3)1.000
  Intraabdominal bleeding3 (0.8)6 (1.1)0.7463 (0.9)3 (0.9)1.000
  Luminal bleeding3 (0.8)2 (0.4)0.4032 (0.6)1 (0.3)0.563
  Stenosis2 (0.5)4 (0.7)0.7182 (0.7)1 (0.3)0.563
  Intestinal motility disorder0 (0)6 (1.1)0.0870 (0)5 (1.6)0.062
  Leakage1 (0.3)2 (0.4)0.7990 (0)1 (0.3)0.317
  Fistula0 (0)2 (0.4)0.5170 (0)1 (0.3)0.317
  Pulmonary complications0 (0)5 (0.9)0.0850 (0)4 (1.3)0.124
  Urinary complications1 (0.3)2 (0.4)0.7931 (0.3)1 (0.3)1.000
  Hepatic complications0 (0)2 (0.4)0.5170 (0)0 (0)
Clavien–Dindo classification
 Grade I3 (0.3)6 (1.1)0.7452 (0.6)4 (1.3)0.686
 Grade II4 (1.1)14 (2.6)0.1463 (0.9)6 (1.9)0.505
 Grade IIIa8 (2.1)17 (3.1)0.4156 (1.9)8 (2.5)0.788
 Grade IIIb0 (0)10 (1.8)0.0070 (0)8 (2.5)0.007
 Grade IVa0 (0)1 (0.2)0.4070 (0)0 (0)
 Grade IVb0 (0)0 (0)0 (0)0 (0)
 Grade V0 (0)2 (0.4)0.5170 (0)2 (0.6)0.499
Complication requiring major intervention (≥ grade IIIa)8 (2.1)30 (5.5)0.0116 (1.9)18 (5.7)0.020
Mortality within 30 days0 (0)2 (0.4)0.5170 (0)2 (0.6)0.499

PSM propensity score matching, SD standard deviation.

Operative outcomes and surgical complications of gastric GIST patients treated by laparoscopic versus open resection. PSM propensity score matching, SD standard deviation. The operation time was shorter in the laparoscopic group than in the open group before PSM (113.9 ± 58.6 min vs. 125.5 ± 71.3 min, P = 0.011). After PSM, the operation time of the laparoscopic group was longer than that of the open group (114.0 ± 57.0 min vs. 100.8 ± 54.5 min, P = 0.003) (Table 2). Regardless of PSM, tumor rupture during surgery was not detected in the laparoscopic group. The laparoscopic group showed a significantly lower rate of tumor rupture during surgery than the open group, either before or after PSM (all P < 0.05). Before PSM, 13 patients experienced tumor rupture during open surgery (Table 2). Of the 373 patients who were initially planned for laparoscopic surgery, 14 patients (3.8%) required conversion to open surgery. Detailed explanations for the reason of each case that required conversion to open surgery were described in Supplementary Table 1. The favorable or unfavorable location did not determine the conversion, regardless of PSM. However, the conversion rate was significantly higher in tumors > 5 cm than in those < 5 cm, either before or after PSM (all P < 0.05) (Supplementary Table 2).

Surgical outcomes and complications by subgroup analysis

Multivariate logistic regression analysis revealed that open resection, longer operation time, tumor size larger than 5 cm, and unfavorable locations were independent risk factors for overall complications (Supplementary Table 3). Because, the rate of overall complications can vary depending on the tumor size and locational preferences, subgroup analyses for surgical outcomes including complications were performed between laparoscopic versus open resection, according to the tumor size and locational preferences. Regarding the subgroup analysis according to tumor size, the complication rates were not different in patients with tumors ≤ 5 cm between the two groups, but the laparoscopic group had a lower rate of overall (3.1% vs. 16.2%, P = 0.012) and major complication (1.6% vs. 12.2%, P = 0.020) than the open group, in patients with tumors > 5 cm. The hospitalization days were shorter in the laparoscopic group than in the open group, either in patients with tumors ≤ 5 cm or > 5 cm (all P < 0.05, Table 3).
Table 3

Operative outcomes and surgical complications of patients with gastric GISTs according to tumor size.

VariableTumor size ≤ 5 cmP valueTumor size > 5 cmP value
Laparoscopic group(N = 254)Open group(N = 244)Laparoscopic group(N = 64)Open group(N = 74)
Operation time (minute)
 Overall112.5 ± 58.9100.0 ± 53.30.015120.1 ± 48.8103.5 ± 58.60.073
Conversion to open surgery5 (2.0)6 (9.4)
Tumor rupture during surgery0 (0)3 (1.2)0.1170 (0)3 (4.1)0.248
Hospital days (mean ± SD)
 Overall6.5 ± 4.28.8 ± 6.7 < 0.0016.6 ± 2.79.0 ± 5.90.003
Postoperative complications
 Total number of cases with complication9 (3.5)13 (5.3)0.3872 (3.1)12 (16.2)0.012
  Wound1 (0.4)5 (2.0)0.1161 (1.6)5 (6.8)0.216
  Fluid collection1 (0.4)0 (0)0.3270 (0)1 (1.4)0.351
  Intraabdominal bleeding3 (1.2)3 (1.2)0.9610 (0)0 (0)
  Luminal bleeding1 (0.4)1 (0.4)0.9771 (1.6)0 (0)0.464
  Stenosis2 (0.9)1 (0.5)0.6000 (0)0 (0)
  Intestinal motility disorder0 (0)2 (0.8)0.2400 (0)3 (4.1)0.248
  Leakage0 (0)1 (0.4)0.4900 (0)0 (0)
  Fistula0 (0)0 (0)0 (0)1 (1.4)0.351
  Pulmonary complications0 (0)2 (0.8)0.2400 (0)2 (2.7)0.499
  Urinary complications1 (0.4)0 (0)0.3270 (0)1 (1.4)0.351
Clavien–Dindo classification
 Grade I1 (0.4)3 (1.2)0.3641 (1.6)1 (1.4)0.918
 Grade II3 (1.2)3 (1.2)1.0000 (0)3 (4.1)0.248
 Grade IIIa5 (2.0)4 (1.6)0.7831 (1.6)4 (5.4)0.373
 Grade IIIb0 (0)4 (1.6)0.0570 (0)4 (5.4)0.123
 Grade IVa0 (0)0 (0)0 (0)0 (0)
 Grade IVb0 (0)0 (0)0 (0)0 (0)
 Grade V0 (0)1 (0.4)0.4900 (0)1 (1.4)0.351
Complication requiring major intervention (≥ grade IIIa)5 (2.0)9 (3.7)0.2871 (1.6)9 (12.2)0.020
Mortality within 30 days0 (0)1 (0.4)0.4900 (0)1 (1.4)0.351

SD standard deviation.

Operative outcomes and surgical complications of patients with gastric GISTs according to tumor size. SD standard deviation. According to locational preference, the rate of overall complications was not different between the two groups for tumors in favorable locations. However, the laparoscopic group had a significantly lower rate of complications than the open group for tumors in unfavorable locations (4.0% vs. 10.1%, P = 0.040). The hospitalization days of the laparoscopic group were shorter than those of the open group, indiscriminate of locational preference (all P < 0.05, Table 4).
Table 4

Operative outcomes and surgical complications according to locational preference (favorable versus unfavorable).

VariableFavorable locationP valueUnfavorable locationP value
Laparoscopic group(N = 145)Open group(N = 130)Laparoscopic group(N = 173)Open group(N = 188)
Operation time (minute)
 Overall113.4 ± 59.6100.5 ± 59.40.079114.6 ± 54.8101.1 ± 51.10.017
Conversion to open surgery3 (2.1)8 (4.6)
Tumor rupture during surgery0 (0)1 (0.8)0.4730 (0)5 (2.7)0.062
Hospital days (mean ± SD)
 Overall6.7 ± 5.28.6 ± 5.70.0066.6 ± 4.88.9 ± 7.0 < 0.001
Postoperative complications
 Total number of cases with complication4 (2.8)6 (4.6)0.5257 (4.0)19 (10.1)0.040
  Wound1 (0.7)3 (2.3)0.3471 (0.6)7 (3.7)0.069
  Fluid collection1 (0.7)0 (0)0.3430 (0)1 (0.5)0.337
  Intraabdominal bleeding0 (0)1 (0.8)0.4733 (1.7)2 (1.1)0.674
  Luminal bleeding1 (0.7)1 (0.8)0.9381 (0.6)0 (0)0.479
  Stenosis0 (0)0 (0)2 (1.2)1 (0.5)0.609
  Intestinal motility disorder0 (0)0 (0)0 (0)5 (2.7)0.062
  Leakage0 (0)0 (0)0 (0)1 (0.5)0.337
  Fistula0 (0)1 (0.8)0.4730 (0)0 (0)
  Pulmonary complications0 (0)1 (0.8)0.4730 (0)3 (1.6)0.249
  Urinary complications1 (0.7)1 (0.8)0.9380 (0)0 (0)
Clavien–Dindo classification
 Grade I1 (0.7)3 (2.3)0.3471 (0.6)1 (0.5)0.953
 Grade II2 (1.4)1 (0.8)0.6271 (0.6)5 (2.7)0.217
 Grade IIIa1 (0.7)3 (2.3)0.3475 (2.9)6 (3.2)0.868
 Grade IIIb0 (0)0 (0)0 (0)7 (3.7)0.015
 Grade IVa0 (0)0 (0)0 (0)0 (0)
 Grade IVb0 (0)0 (0)0 (0)0 (0)
 Grade V0 (0)1 (0.8)0.4730 (0)1 (0.5)0.337
Complication requiring major intervention (grade ≥ IIIa)1 (0.7)4 (3.1)0.1925 (2.9)14 (7.4)0.061
Mortality within 30 days0 (0)1 (0.8)0.4730 (0)1 (0.5)0.337

SD standard deviation.

Operative outcomes and surgical complications according to locational preference (favorable versus unfavorable). SD standard deviation.

Oncologic outcomes

Before PSM, the open group had more patients with adjuvant chemotherapy, longer follow-up duration, recurrence, and death. The recurrence-free survival rates of the laparoscopic group were superior to those of the open groups (all P < 0.05). After PSM, the parameters related to oncologic outcomes were not different between the two groups. The recurrence-free survival rates were not different between the two groups, regardless of tumor size, locational preference, and NIH risk classification (all P > 0.05) (Table 5, Fig. 1).
Table 5

Oncologic outcomes for laparoscopic versus open resection before and after propensity score matching.

VariablesBefore PSMP valueAfter PSMP value
Laparoscopic group(N = 373)Open group(N = 542)Laparoscopic group(N = 318)Open group(N = 318)
Chemotherapy
Preoperative1 (0.3)6 (1.1)0.2511 (0.3)2 (0.6)0.563
Adjuvant7 (1.9)52 (9.6) < 0.0017 (2.2)7 (2.2)0.000
Duration of follow-up
Mean93.6103.5 < 0.00195.198.80.114
Median (range)88.0 (11.0–164.7)106.4 (0.1–167.9)88.5 (25.2–164.7)100.7 (0.1–144.2)
Recurrence
Total number13 (3.5)72(13.3) < 0.00110 (3.1)16 (5.0)0.317
Stomach5 (1.3)16 (3.0)0.1215 (1.6)3 (0.9)0.725
Small bowel0 (0)1 (0.2)0.4070 (0)1 (0.3)0.317
Liver2 (0.5)36 (6.6) < 0.0011 (0.3)7 (2.2)0.069
Peritoneum5 (1.3)20 (3.7)0.0384 (1.3)2 (0.6)0.686
Bone0 (0)3 (0.6)0.2750 (0)0 (0)
Wound0 (0)1 (0.3)0.4080 (0)1 (0.3)0.317
Lung0 (0)1 (0.2)0.4070 (0)1 (0.3)0.317
Axilla1 (0.3)3 (0.6)0.6491 (0.3)2 (0.6)0.563
Alive
Total number365 (97.9)499 (92.1) < 0.001311 (97.8)307 (96.5)0.474
with recurrence free355 (95.2)448 (82.7) < 0.001303 (95.3)296 (93.1)0.173
with recurrence10 (2.7)51 (9.4) < 0.0018 (2.5)11 (3.5)0.643
Death
Total number8 (2.1)43 (7.9) < 0.0017 (2.2)11 (3.5)0.474
Died due to GIST3 (0.8)21 (3.9)0.0052 (0.6)5 (1.6)0.451
Died of other causes5 (1.3)22 (4.1)0.0175 (1.6)6 (1.9)0.761

GIST gastrointestinal stromal tumor, PSM propensity score matching.

Figure 1

Comparison of disease-free survival between the laparoscopic and open groups. (a) Disease-free survival in all patients, before 1:1 propensity score matching. (b) Disease-free survival in all patients, after 1:1 propensity score matching. (c) Disease-free survival in patients with tumor ≤ 5 cm, after 1:1 propensity score matching. (d) Disease-free survival in patients with tumor > 5 cm, after 1:1 propensity score matching. (e) Disease-free survival in patients with tumor at favorable location, after 1:1 propensity score matching. (f) Disease-free survival in patients with tumor at unfavorable location, after 1:1 propensity score matching. (g) Disease-free survival in patients with very low to intermediate risk by National Institutes of Health classification, after 1:1 propensity score matching. (h) Disease-free survival in patients with high risk by National Institutes of Health classification, after 1:1 propensity score matching.

Oncologic outcomes for laparoscopic versus open resection before and after propensity score matching. GIST gastrointestinal stromal tumor, PSM propensity score matching. Comparison of disease-free survival between the laparoscopic and open groups. (a) Disease-free survival in all patients, before 1:1 propensity score matching. (b) Disease-free survival in all patients, after 1:1 propensity score matching. (c) Disease-free survival in patients with tumor ≤ 5 cm, after 1:1 propensity score matching. (d) Disease-free survival in patients with tumor > 5 cm, after 1:1 propensity score matching. (e) Disease-free survival in patients with tumor at favorable location, after 1:1 propensity score matching. (f) Disease-free survival in patients with tumor at unfavorable location, after 1:1 propensity score matching. (g) Disease-free survival in patients with very low to intermediate risk by National Institutes of Health classification, after 1:1 propensity score matching. (h) Disease-free survival in patients with high risk by National Institutes of Health classification, after 1:1 propensity score matching. Multivariate Cox regression analysis revealed the following independent risk factors: R1 (vs. R0) resection (hazard ratio [HR] = 6.327, 95% confidence interval [CI] = 1.826–21.919, P = 0.004), tumor size > 5 cm (vs. ≤ 5 cm) (HR = 3.080, 95% CI = 1.368–6.934, P = 0.007), mitotic count > 5, ≤ 10 (vs. ≤ 5) (HR = 8.090, 95% CI = 2.651–24.685, P < 0.001), mitotic count > 10 (vs. ≤ 5) (HR = 32.666, 95% CI = 10.586–100.798, P < 0.001), and tumor rupture during surgery (HR = 63.479, 95% CI = 17.407–231.488, P < 0.001) (Table 6).
Table 6

Univariate and multivariate Cox regression analysis for variables to predict the recurrence.

VariablesUnivariate Cox regressionMultivariate Cox regression
BHazard ratio (95% CI)P valueBHazard ratio (95% CI)P value
Age, years per increase0.0061.006 (0.972–1.041)0.740
Male (vs. female)0.4611.586 (0.728–3.453)0.245
Body mass index (kg/m2, per increase) − 0.0690.934 (0.821–1.062)0.296
Laparoscopy (vs. open) − 0.4720.624 (0.283–1.375)0.242
Extent of resection
 Gastrectomy versus wedge or enucleation1.4014.059 (1.629–10.116)0.003
Radicality, R1 (vs. R0 resection)2.1468.550 (2.567–28.484) < 0.0011.8456.327 (1.826–21.919)0.004
Adjuvant therapy2.2389.377 (3.226–27.259) < 0.001
Tumor size
 > 5 cm (vs. ≤ 5 cm)1.6265.082 (2.334–11.064) < 0.0011.1253.080 (1.368–6.934)0.007
Mitotic rate (per 50 HPF)
 > 5, ≤ 10 (vs. ≤ 5)1.9136.771 (2.348–19.524) < 0.0012.0918.090 (2.651–24.685) < 0.001
 > 10 (vs. ≤ 5)3.13522.983 (8.617–61.298) < 0.0013.48632.666 (10.586–100.798) < 0.001
NIH risk classification
 High (vs. very low to intermediate)2.45711.664 (5.290–25.721) < 0.001
Tumor rupture during surgery3.20824.724 (8.467–72.190) < 0.0014.15163.479 (17.407–231.488) < 0.001

Covariates were age, sex, body mass index (kg/m2), laparoscopic approach, extent of resection, radicality, adjuvant therapy, tumor size, mitotic rate, NIH risk classification, tumor rupture during surgery.

CI confidence interval, HPF high power field, NIH National institutes of health.

Univariate and multivariate Cox regression analysis for variables to predict the recurrence. Covariates were age, sex, body mass index (kg/m2), laparoscopic approach, extent of resection, radicality, adjuvant therapy, tumor size, mitotic rate, NIH risk classification, tumor rupture during surgery. CI confidence interval, HPF high power field, NIH National institutes of health.

Discussion

This study reviewed the multicentric database from 13 institutions in Korea and 2 in Japan, with more than 1019 patients who underwent laparoscopic and open resection for primary gastric GIST. Long-term surgical and oncologic outcomes for the treatment of primary gastric GIST have been reported based on this retrospective data[19], and this is a subsequent, collateral study comparing the outcomes between laparoscopic and open surgery. Since resection of gastric GISTs is simple and does not require extensive lymphadenectomy with wide tumor-free margins[20,21], the benefits of laparoscopic surgery for gastric GIST may not be as obvious as in gastric cancer surgery. Moreover, while Korean Laparo-endoscopic Gastrointestinal Surgery Study Group (KLASS) RCTs proved superiority of laparoscopic over open gastrectomy, no other RCTs have demonstrated the beneficial effect of laparoscopic resection for gastric GIST. Therefore, it seems impatient to generalize that a laparoscopic approach is beneficial for GIST surgery. Even, Xiong et al.[18] enrolled more patients than current study, they could only compare 128 cases in each group for analysis after PSM. However, the current study remained the largest number of cases after PSM, with more than 300 patients in each group[16,18]. The PSM was carried out in the direction of preserving the sample size as many as possible, by including only four essential variables that may affect the preference of laparoscopic approach and the patient's clinical course. After eliminating the preferential selection bias with PSM, the clinicopathologic characteristics were balanced between the two groups. The distribution of the propensity score was more concentrated, and the absolute SMDs of matching covariates decreased near 0.1. All these efforts contributed to overcoming the bias of a retrospective approach and provided robustness to the current study. We demonstrated that laparoscopic resection provided superior outcomes, such as shorter hospitalization days, lower rate of tumor rupture, and overall and wound complications than open surgery for the treatment of gastric GIST, even in the early era of the laparoscopic surgery. The patients with tumors larger than 5 cm and in unfavorable locations were also provided with advantages of laparoscopic surgery. Intestinal motility disorder and tumor rupture were not identified in laparoscopic surgery. While the beneficial effects of laparoscopic distal gastrectomy in the KLASS 01 and 02 trials were obtained through the surgeons’ strict quality control[9,10], the results of the current study are more realistic, as they were based on the data generated by the surgeons’ unrefined experience for laparoscopic surgery. The superior surgical outcome of the laparoscopic approach can be explained by the following reasons. First, the highly magnified view through the laparoscopic camera might enable the surgeon to perform more meticulous dissection, which could avoid unexpected bleeding or tumor rupture[9]. Second, less manipulation of the bowel and smaller wound, might enable patients to have early ambulation and return to eating, with less pain and better peristalsis[22,23]. Third, although the annual experience of laparoscopic surgery differed from one person to another (0–100 cases) in the mid to late 1990s, all surgeons participating in current study had at least 5 years of experiences performing 50–150 cases of open gastrectomy per year prior to initiating laparoscopic gastric surgery. From the year of 2003, even surgeons without any experience in laparoscopic procedures began performing at least 30 cases of laparoscopic surgeries for gastric cancer or GIST every year. Besides, resection of gastric GISTs is simple and does not require extensive lymphadenectomy with wide tumor-free margins as in gastric cancer surgery. These various factors might have allowed to provide an opportunity for better realization of minimal invasiveness, which ultimately resulted in faster recovery and better postoperative outcomes, even in the early era of laparoscopic surgery without surgeon’s quality control. Nevertheless, laparoscopic approaches have traditionally been recommended for patients with GISTs less than 5 cm, or in favorable locations, according to the NCCN guidelines[24,25]. Huang et al. reported that the unfavorable group had longer hospital stays and more postoperative complications than the favorable group[26]. We also revealed that tumor size larger (vs. less) than 5 cm and unfavorable (vs. favorable) location were independent risk factors for postoperative complications. For these reasons, it is meaningful to investigate whether laparoscopic surgery can lower the rate of surgical complications under these circumstances. Fortunately, successful laparoscopic resection for gastric GISTs larger than 5 cm has been steadily reported with the largest diameters up to 10.5 cm and 11.5 cm[27,28]. Indeed, the postoperative outcomes of laparoscopic surgery were reported to be comparable or even better with tumors larger than 5 cm[29,30]. Regarding the unfavorable locations, the incidence of grade III–IV postoperative complications from laparoscopic surgery was reported to be significantly less than that of open surgery (2.3% vs. 29.0%, P = 0.001)[26]. This study also demonstrated that laparoscopic resection provided shorter hospital stays and lower complication rates in patients with tumors larger than 5 cm and at unfavorable locations. Despite the superior surgical outcome of laparoscopic surgery, surgeons face skepticism that laparoscopic resection also requires laparotomy at least as large as the size of the tumor to retrieve the specimen. In the open surgery, laparotomy larger than tumor size is often necessary to obtain a better view of the invisible side beyond tumor for safe resection. However, laparoscopic camera can reach and visualize the marginal area beyond the large tumor even in unfavorable locations. Laparoscopic surgery only requires a length of incision that fits the tumor size, with the aid of laparoscopic pouch bag. As the laparoscopic procedures become more minimally invasive, the wound length can be shortened to the minimum size, required only for specimen retrieval[4,31]. Although analysis of the incision length was not possible due to the retrospective nature of the current study, we expect that the shorter wound length would have contributed to the lower rate of wound complication in laparoscopic resection than in open surgery, as in previous studies[32]. Of the 373 cases with laparoscopic resection, 14 cases (3.8%) required conversion to open surgery, lower than that in most reported series (7% [range 0–25])[16,29]. Our study showed that the conversion rate was not related to locational preference. Instead, the conversion rate was higher in patients with tumors larger than 5 cm (Supplementary Table 2). Considering that Kitano et al.[33] first introduced the laparoscopic technique in the field of gastric cancer surgery in 1994, laparoscopic resection for gastric GIST would not have been actively performed in the early 2000s, which is similar to our results (Supplementary Fig. 2). Moreover, the gap in operation time between the laparoscopic and open groups narrowed and improved from 2006 (108.53 ± 63.43 min. vs. 97.62 ± 46.36 min, P = 0.177), compared to the year before 2006 (119.87 ± 48.68 min. vs. 101.94 ± 57.05 min., P = 0.001). Recent studies reported a faster operation time in laparoscopic resection than in open surgery for gastric GISTs larger than 5 cm[29]. With advances in laparoscopic techniques, the rate of conversion to open surgery may reduce further. A superior RFS in laparoscopic resection than in open surgery, can be explained by the differences in the clinical and pathological characteristics, which exert a great impact on the oncologic outcome of GIST[34]. Following our elimination of confounding variables using 1:1 PSM, we showed no significant difference in the recurrence-free survival between the laparoscopic and open groups, even in patients with tumors larger than 5 cm, at unfavorable locations, and in high-risk groups. Several studies including our previous research reported that male sex and non-gastric location were also risk factors for recurrence after resection of gastric GIST[19,20,35]. In the current study, multivariate Cox regression analysis revealed that tumor size > 5 (vs. ≤ 5) cm, higher mitotic count, R1 (vs. R0) resection, and tumor rupture during surgery were independent risk factors for the recurrence of gastric GIST, after eliminating confounding effects by PSM. Laparoscopic or open approaches were not associated with recurrence. The patients with laparoscopic resection and open surgery had similar recurrence and survival rates, by balancing the baseline characteristics of patients after PSM. This study has some limitations. First, the patients were enrolled from the year 2000, when surgical methods, laparoscopic indications, and pre and postoperative treatment guidelines for gastric GIST were not standardized. Since the worldwide incidence of gastric GIST is rare, it took about 8 years to recruit more than 1000 patients. Additionally, imatinib mesylate (Gleevec) was covered by the Korean health insurance system from June 2001. Therefore, the trends in treatment for gastric GIST may have changed during our study period. Nevertheless, we tried to further highlight the advantages of laparoscopic surgery by demonstrating that laparoscopic approach was superior to open surgery in the treatment of gastric GISTs even in the early 2000s, when laparoscopic techniques were not fully advanced. Second, since we were unable to review the detailed pathologic information of patients prior to the introduction of electrical medical records, the staining information for CD117 and CD34 was not available in some patients; we only included patients with clear medical records who were diagnosed with gastric GIST after surgical resection. In each institution, the diagnosis of gastric GIST was confirmed by reviewing the patient's pathologic findings, which included both typical morphological features and information from IHC staining. We inevitably included patients without information on IHC staining for CD117 and CD34 to preserve as many cases as possible. All patients negative for CD117 were positive for CD34, and the remaining patients with available data on IHC also showed a similar rate of distribution of C-kit positivity as in previous studies[26,36]. Third, detailed information on accidental intraoperative injury to adjacent organs could not be analyzed for similar reasons. Fourth, although the concept of favorable and unfavorable locations had not been established during the period 2000–2007, only patients with clear information about both longitudinal and circumferential locations on the endoscopic and surgical records could be included in this study. Therefore, we were able to classify patients with favorable and unfavorable locations by retrospective reviewing the longitudinal and circumferential locations[24,26]. Fifth, although PSM is a good method to reduce selection bias, it cannot eliminate this bias completely as RCT would be able to. We excluded only the cases with distant metastasis or invasion to adjacent organs, and then matched the variables determining the preferences for the laparoscopic approach, to preserve as many cases as possible. Therefore, similar recurrence and survival rates between laparoscopic resection and open surgery were obtained by balancing baseline characteristics, not due to the washing out effect of PSM. Finally, PSM analysis inevitably excluded the most of cases requiring combined resection and patients with tumors larger than 15 cm, the superiority of laparoscopic surgery could not be analyzed in these population (Table 1). Future studies are expected to provide answer for these issues.

Conclusions

Even in the early era of laparoscopic surgery with unrefined experiences, laparoscopic resection could provide a lower rate of complications and shorter hospitalization for patients with gastric GIST than open surgery, without compromising oncological safety. Since its first introduction in the early 1990s, laparoscopic gastrectomy has technologically revolutionized the treatment of gastric cancer and almost 30 years have passed. Considering the development of laparoscopic technology over decades, and the current study having large number of cases with more than 300 in each group after 1:1 matching, wider adoption of laparoscopic resection is expected in clinical practice, even in patients with tumor sizes larger than 5 cm and in unfavorable locations.

Materials and methods

Study design and cohorts

From 13 institutions in Korea and 2 institutions in Japan, we retrospectively reviewed the prospectively collected database of 1019 patients who were diagnosed with gastric GIST after surgical resection between January 2000 and December 2007. In each institution, the diagnosis of gastric GIST was confirmed by reviewing the patient's pathologic findings, which included typical morphological features and staining for immunohistochemistry (IHC). The exclusion criteria were as follows: (1) distant metastasis or invasion of the adjacent organs; (2) concomitant other primary malignancy; and (3) cases with missing data (Fig. 2).
Figure 2

The flow chart for the patient selection model.

The flow chart for the patient selection model. The primary outcomes were surgical complications. Secondary outcomes included disease-free survival, rate of recurrence, and survival. Patients were divided into two groups: those who underwent laparoscopic gastric resection (laparoscopic group) and those who underwent open surgery (open group). The prospectively collected clinicopathologic data and operative parameters from each institution were retrospectively reviewed. Mitotic rate was defined as the number of mitoses per 50 high-power fields. Risk stratification was performed according to the modified National Institutes of Health (NIH) risk classification. Although, the concept of favorable and unfavorable locations had not been established during the period 2000–2007, we were able to classify patients according to unfavorable (the gastroesophageal junction, the lesser curvature, the posterior wall, the antrum, and the pylorus) and favorable locations (all locations except the unfavorable locations, which included the greater curvature and anterior wall of the stomach), by retrospectively reviewing endoscopic and operative records with longitudinal and circumferential locations[24,26]. Therefore, only patients with clear information about both longitudinal and circumferential locations on the endoscopic and surgical records were included in this study. Patients were followed up every 6 months or annually, and the follow-up information included adjuvant treatment, survival or death, and recurrences. This study was approved by the Institutional Review Board (IRB) of Seoul National University Hospital (IRB number: H2006-176-1135) and each participating institution, conducted in accordance with the 1964 Declaration of Helsinki and newer amendments.

Propensity score matching

Each case from the laparoscopic group was 1:1 propensity score matched to control cases in the open group. The matching variables included tumor size, mitotic rate, locational preference (favorable, or unfavorable), and adjuvant chemotherapy. The propensity score of each patient was estimated by logistic regression (SPSS version 25; IBM Corp., Armonk, NY) and matched nearest-neighbor value within a caliper 0.02 times the standard deviation of the estimated score. After 1:1 PSM, the balance of covariates between the laparoscopic and open groups was measured by calculating the standardized mean difference. A standardized mean difference (SMD) of less than 0.1 was considered to achieve balance and SMD ranging from 0.1 to 0.25 were considered as acceptable disparity between groups[37].

Surgical and oncologic outcome

The operative outcomes including surgical complications, operation time, tumor rupture during surgery and hospitalization days were compared between the laparoscopic and open groups, both before and after 1:1 PSM. After performing multivariate logistic regression analysis to reveal the independent factors for surgical complications, we separately collected the patients with such risk factors to determine the presence of complications. We then compared the operative outcomes including surgical complications between the laparoscopic and open groups, for these subgroups. Complication categories were based on the categories used in previous phase III multi-center randomized controlled trials evaluating the complications of laparoscopic gastrectomy. Intestinal motility disorder refers to the peristaltic problem in intestinal tract including mechanical or paralytic ileus, intestinal obstructions[38,39]. Survival periods were defined as the time from operation to death associated with the GIST or not, which were censored at the final follow-up visit. The recurrence-free survival was calculated as the time from operation to the event of recurrent disease. Recurrence-free survival was compared between the laparoscopic and open groups, either before or after 1:1 PSM. Subgroup analysis for recurrence-free survival was performed according to tumor size, locational preference, and NIH risk classification. Multivariate analysis with Cox proportional hazard regression was used to determine the independent prognostic factors to predict the tumor recurrence.

Statistical analysis

The chi-square test was used for categorical variables, and Student’ s t-test was used to compare continuous variables between the two groups. All tests were two-sided, and a P value of < 0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics version 25. The recurrence-free survival was assessed by Kaplan–Meier analysis and the log-rank test.

Compliance with ethical standards

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB number: H2006-176-1135) and each participating institution. The requirement for informed consent was waived by the IRB of Seoul National University Hospital (IRB number: H2006-176-1135) and each participating institution, because of the retrospective nature of this study. Supplementary Information.
  38 in total

1.  Long-term quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer.

Authors:  K Yasuda; N Shiraishi; T Etoh; A Shiromizu; M Inomata; S Kitano
Journal:  Surg Endosc       Date:  2007-05-04       Impact factor: 4.584

2.  Open versus minimally invasive resection of gastric GIST: a multi-institutional analysis of short- and long-term outcomes.

Authors:  Danielle A Bischof; Yuhree Kim; Rebecca Dodson; M Carolina Jimenez; Ramy Behman; Andrei Cocieru; Dan G Blazer; Sarah B Fisher; Malcolm H Squires; David A Kooby; Shishir K Maithel; Ryan T Groeschl; T Clark Gamblin; Todd W Bauer; Paul J Karanicolas; Calvin Law; Fayez A Quereshy; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2014-04-24       Impact factor: 5.344

Review 3.  Laparoscopic surgery versus open resection in patients with gastrointestinal stromal tumors: An updated systematic review and meta-analysis.

Authors:  Hanchu Xiong; Ji Wang; Yunlu Jia; Chenyang Ye; Yi Lu; Cong Chen; Jianguo Shen; Yongxia Chen; Wenhe Zhao; Linbo Wang; Jichun Zhou
Journal:  Am J Surg       Date:  2017-04-05       Impact factor: 2.565

4.  Gastrointestinal stromal tumors, version 2.2014.

Authors:  Margaret von Mehren; R Lor Randall; Robert S Benjamin; Sarah Boles; Marilyn M Bui; Ephraim S Casper; Ernest U Conrad; Thomas F DeLaney; Kristen N Ganjoo; Suzanne George; Ricardo J Gonzalez; Martin J Heslin; John M Kane; Joel Mayerson; Sean V McGarry; Christian Meyer; Richard J O'Donnell; Alberto S Pappo; I Benjamin Paz; John D Pfeifer; Richard F Riedel; Scott Schuetze; Karen D Schupak; Herbert S Schwartz; Brian A Van Tine; Jeffrey D Wayne; Mary Anne Bergman; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2014-06       Impact factor: 11.908

Review 5.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.

Authors:  Heikki Joensuu; Aki Vehtari; Jaakko Riihimäki; Toshirou Nishida; Sonja E Steigen; Peter Brabec; Lukas Plank; Bengt Nilsson; Claudia Cirilli; Chiara Braconi; Andrea Bordoni; Magnus K Magnusson; Zdenek Linke; Jozef Sufliarsky; Massimo Federico; Jon G Jonasson; Angelo Paolo Dei Tos; Piotr Rutkowski
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

6.  Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.

Authors:  Bengt Nilsson; Per Bümming; Jeanne M Meis-Kindblom; Anders Odén; Aydin Dortok; Bengt Gustavsson; Katarzyna Sablinska; Lars-Gunnar Kindblom
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

7.  Meta-Analysis on the Efficacy and Safety of Laparoscopic Surgery for Large Gastric Gastrointestinal Stromal Tumors.

Authors:  Miao Yu; Deng-Chao Wang; Jian Wei; Yue-Hua Lei; Zhao-Jun Fu; Yu-Hui Yang
Journal:  Am Surg       Date:  2020-10-07       Impact factor: 0.688

8.  Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment.

Authors:  Martin E Blackstein; Jean-Yves Blay; Christopher Corless; David K Driman; Robert Riddell; Denis Soulières; Carol J Swallow; Shailendra Verma
Journal:  Can J Gastroenterol       Date:  2006-03       Impact factor: 3.522

9.  Laparoscopic Versus Open Surgery for Gastric Gastrointestinal Stromal Tumors: What Is the Impact on Postoperative Outcome and Oncologic Results?

Authors:  Guillaume Piessen; Jérémie H Lefèvre; Magalie Cabau; Alain Duhamel; Héléne Behal; Thierry Perniceni; Jean-Yves Mabrut; Jean-Marc Regimbeau; Sylvie Bonvalot; Guido A M Tiberio; Muriel Mathonnet; Nicolas Regenet; Antoine Guillaud; Olivier Glehen; Pascale Mariani; Quentin Denost; Léon Maggiori; Léonor Benhaim; Gilles Manceau; Didier Mutter; Jean-Pierre Bail; Bernard Meunier; Jack Porcheron; Christophe Mariette; Cécile Brigand
Journal:  Ann Surg       Date:  2015-11       Impact factor: 12.969

10.  Long-Term Surgical Outcome of 1057 Gastric GISTs According to 7th UICC/AJCC TNM System: Multicenter Observational Study From Korea and Japan.

Authors:  Min-Chan Kim; Jeong-Hwan Yook; Han-Kwang Yang; Hyuk-Joon Lee; Tae-Sung Sohn; Woo-Jin Hyung; Seung-Wan Ryu; Yukinori Kurokawa; Young-Woo Kim; Sang-Uk Han; Hyung-Ho Kim; Do-Joong Park; Wook Kim; Sang-Il Lee; Haruhiko Cho; Gyu-Seok Cho; Jin-Jo Kim; Ki-Han Kim; Moon-Won Yoo
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.